3C1

3C1 is a monoclonal antibody that targets the highly conserved central repeat region (specifically the NANP major repeat region) of the Plasmodium falciparum circumsporozoite protein (PfCSP). PfCSP is the dominant antigen on the surface of malaria sporozoites, making it a key target for neutralizing antibodies. Developed by the Aaron Diamond AIDS Research Center (ADARC) in collaboration with Columbia University, Rockefeller University, Otsuka, and the PATH Malaria Vaccine Initiative, 3C1 is designed to neutralize sporozoites before they can infect hepatocytes, thereby preventing the pre-erythrocytic stage of malaria infection. Preclinical studies have demonstrated that 3C1 exhibits high titers and potent protective efficacy against sporozoite challenge, outperforming historical standard antibodies like 2A10. Ongoing research is focused on structural characterization, humanization, and the development of bispecific antibody combinations to optimize its prophylactic and therapeutic potential against Plasmodium falciparum malaria.

Other names

anti-PfCSP monoclonal antibody 3C1chimeric 3C1-hIgG1chimeric3C1-hIgG1chimeric-3C1-hIgG1mAb 3C1mAb3C1mAb-3C1monoclonal antibody 3C1